```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptacrs1614

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HOME' AT 16:58:14 ON 10 DEC 2007
FILE 'HOME' ENTERED AT 16:58:14 ON 10 DEC 2007
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:58:23 ON 10 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    9 DEC 2007  HIGHEST RN 957198-80-0
DICTIONARY FILE UPDATES:   9 DEC 2007  HIGHEST RN 957198-80-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10595691.str
```





chain nodes :
16 17 18 19 20 21 22 23 24 31 32 33 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 25 26 27 28 29 30 34 35 36 37 38 39
chain bonds :
2-15 7-24 12-16 16-17 17-18 18-19 19-20 20-21 20-22 20-23 24-26 29-32 30-31 32-33 33-35 39-40
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 11-12 11-15 12-13 13-14 14-15 25-26 25-30 26-27 27-28 28-29 29-30 34-35 34-39 35-36 36-37 37-38 38-39
exact/norm bonds :
7-24 11-12 11-15 12-13 13-14 14-15 16-17 17-18 19-20 20-21 20-22 24-26 29-32 32-33
exact bonds :
2-15 12-16 18-19 20-23 30-31 33-35 39-40
normalized bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 25-26 25-30 26-27 27-28 28-29 29-30 34-35 34-39 35-36 36-37 37-38 38-39

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS 33:CLASS 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:CLASS

L1 STRUCTURE UPLOADED

```
=> s l1
SAMPLE SEARCH INITIATED 16:58:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        4 TO ITERATE

100.0% PROCESSED        4 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            4 TO      200
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 16:58:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      100 TO ITERATE

100.0% PROCESSED      100 ITERATIONS                                17 ANSWERS
SEARCH TIME: 00.00.01

L3            17 SEA SSS FUL L1

=> s l1 fam ful
FULL SEARCH INITIATED 16:58:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       56 TO ITERATE

100.0% PROCESSED       56 ITERATIONS                                17 ANSWERS
SEARCH TIME: 00.00.01

L4            17 SEA FAM FUL L1

=> file caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                239.35     239.56

FILE 'CAPLUS' ENTERED AT 16:59:04 ON 10 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 10 Dec 2007  VOL 147 ISS 25
FILE LAST UPDATED: 7 Dec 2007  (20071207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l4
```

```
L5         241 L4

=> s l5 and py<=2003
      23975029 PY<=2003
L6           20 L5 AND PY<=2003

=> s l6 and head
         149373 HEAD
          31395 HEADS
         164076 HEAD
                (HEAD OR HEADS)
L7            4 L6 AND HEAD

=> d l7 ibib abs 1-4

L7   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2004:2613  CAPLUS
DOCUMENT NUMBER:          140:53400
TITLE:                    Cancer biomarker expression/activation-based method
                          for predicting response to HER1/HER2-directed cancer
                          therapy
INVENTOR(S):              Bacus, Sarah S.
PATENT ASSIGNEE(S):       Ventana Medical Systems, Inc., USA; Smithkline Beecham
                          Corporation
SOURCE:                   PCT Int. Appl., 35 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ----------------    ----   --------    --------------------    --------
     WO 2004000101        A2    20031231    WO 2003-US19697         20030619 <--
     WO 2004000101        A3    20060908
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003247602        A1    20040106    AU 2003-247602          20030619
PRIORITY APPLN. INFO.:                     US 2002-389795P     P    20020619
                                           US 2002-432811P     P    20021211
                                           WO 2003-US19697     W    20030619
AB   This invention provides methods for determining or predicting response to
     HER1/HER2-directed cancer therapy in an individual.  The methodol. of the
     invention includes assaying a tumor sample with one or more reagents that
     detect expression and/or activation of predictive biomarkers for cancer,
     e.g. growth factor receptors, growth factor receptor ligands, and growth
     factor receptor-related downstream signaling mols.

L7   ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2004:2612  CAPLUS
DOCUMENT NUMBER:          140:53399
TITLE:                    Predictive markers in cancer therapy
INVENTOR(S):              Bacus, Sarah S.; Herrle, Myra R.; Kirk, L. Edward;
                          Spector, Neil L.; Stocum, Michael T.; Xia, Wenle
```

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000094	A2	20031231	WO 2003-US12739	20030424 <--
WO 2004000094	A3	20070614		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA

AU 2003235470	A1	20040106	AU 2003-235470		20030424
EP 1810034	A2	20070725	EP 2003-724213		20030424
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, LT, LV					
US 2006094068	A1	20060504	US 2005-529922		20050330
PRIORITY APPLN. INFO.:			US 2002-389795P	P	20020619
			US 2002-432811P	P	20021211
			US 2002-432943P	P	20021211
			US 2003-451978P	P	20030303
			WO 2003-US12739	W	20030424

AB Mol. markers useful in medicine response tests are provided, as an aid in determining whether an individual subject's tumor is responding to treatment with EGF and/or erbB2 inhibitors. Markers include phosphorylated ERK protein.

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:668812 CAPLUS
DOCUMENT NUMBER: 138:280796
TITLE: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
AUTHOR(S): Xia, Wenle; Mullin, Robert J.; Keith, Barry R.; Liu, Lei-Hua; Ma, Hong; Rusnak, David W.; Owens, Gary; Alligood, Krystal J.; Spector, Neil L.
CORPORATE SOURCE: GlaxoSmithKline, Department of Discovery Medicine, Research Triangle Park, North Carolina, NC, 27709-3398, USA
SOURCE: Oncogene (2002), 21(41), 6255-6263
CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and survival signals. Here we show that a small mol., GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines. GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and

AKT, downstream effectors of proliferation and cell survival, resp. Complete inhibition of activated AKT in erbB2 overexpressing cells correlated with a 23-fold increase in apoptosis compared with vehicle controls. EGF, often elevated in cancer patients, did not reverse the inhibitory effects of GW572016. These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts. Erk1/2 and AKT represent potential biomarkers to assess the clin. activity of GW572016. Inhibition of activated AKT in EGFR or erbB2-dependent tumors by GW572016 may lead to tumor regressions when used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:555376 CAPLUS
DOCUMENT NUMBER: 137:119644
TITLE: 4-Quinazolineamine derivative combination with other antineoplastic agent for cancer treatment, and compound preparation.
INVENTOR(S): Lackey, Karen Elizabeth; Spector, Neil; Wood, Edgar Raymond, III; Xia, Wenle
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056912	A2	20020725	WO 2002-US1130	20020114 <--
WO 2002056912	A3	20030522		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002236765	A1	20020730	AU 2002-236765	20020114 <--
EP 1353693	A2	20031022	EP 2002-703127	20020114 <--
EP 1353693	B1	20050316		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004523522	T	20040805	JP 2002-557419	20020114
EP 1488809	A1	20041222	EP 2004-77577	20020114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
EP 1512413	A2	20050309	EP 2004-78283	20020114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
AT 290882	T	20050415	AT 2002-703127	20020114
ES 2236481	T3	20050716	ES 2002-2703127	20020114
US 2004053946	A1	20040318	US 2003-466290	20030715
US 7141576	B2	20061128		
US 2007148261	A1	20070628	US 2006-548413	20061011

```
PRIORITY APPLN. INFO.:                      US 2001-262402P     P  20010116
                                            EP 2002-703127      A3 20020114
                                            WO 2002-US1130      W  20020114
                                            US 2003-466290      A1 20030715
OTHER SOURCE(S):          MARPAT 137:119644
AB   A method of treating cancer is described which includes administration of
     a 4-quinazolineamine (preparation included) and at least one other
     antineoplastic agent.  Also described is a pharmaceutical combination
     including the 4-quinazolineamines.


=> s l7 and akt
         14934 AKT
            27 AKTS
         14947 AKT
                (AKT OR AKTS)
L8            4 L7 AND AKT

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    27.22     266.78

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -3.12      -3.12

STN INTERNATIONAL LOGOFF AT 17:11:27 ON 10 DEC 2007


Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 02  LMEDLINE coverage updated
 NEWS  3  JUL 02  SCISEARCH enhanced with complete author names
 NEWS  4  JUL 02  CHEMCATS accession numbers revised
 NEWS  5  JUL 02  CA/CAplus enhanced with utility model patents from China
 NEWS  6  JUL 16  CAplus enhanced with French and German abstracts
 NEWS  7  JUL 18  CA/CAplus patent coverage enhanced
 NEWS  8  JUL 26  USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS  9  JUL 30  USGENE now available on STN
 NEWS 10  AUG 06  CAS REGISTRY enhanced with new experimental property tags
 NEWS 11  AUG 06  FSTA enhanced with new thesaurus edition
 NEWS 12  AUG 13  CA/CAplus enhanced with additional kind codes for granted
                  patents
 NEWS 13  AUG 20  CA/CAplus enhanced with CAS indexing in pre-1907 records
```

```
 NEWS 14  AUG 27  Full-text patent databases enhanced with predefined
                  patent family display formats from INPADOCDB
 NEWS 15  AUG 27  USPATOLD now available on STN
 NEWS 16  AUG 28  CAS REGISTRY enhanced with additional experimental
                  spectral property data
 NEWS 17  SEP 07  STN AnaVist, Version 2.0, now available with Derwent
                  World Patents Index
 NEWS 18  SEP 13  FORIS renamed to SOFIS
 NEWS 19  SEP 13  INPADOCDB enhanced with monthly SDI frequency
 NEWS 20  SEP 17  CA/CAplus enhanced with printed CA page images from
                  1967-1998
 NEWS 21  SEP 17  CAplus coverage extended to include traditional medicine
                  patents
 NEWS 22  SEP 24  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 23  OCT 02  CA/CAplus enhanced with pre-1907 records from Chemisches
                  Zentralblatt
 NEWS 24  OCT 19  BEILSTEIN updated with new compounds
 NEWS 25  NOV 15  Derwent Indian patent publication number format enhanced
 NEWS 26  NOV 19  WPIX enhanced with XML display format
 NEWS 27  NOV 30  ICSD reloaded with enhancements
 NEWS 28  DEC 04  LINPADOCDB now available on STN

 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:28:10 ON 10 DEC 2007

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21

FILE 'REGISTRY' ENTERED AT 17:28:19 ON 10 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 DEC 2007 HIGHEST RN 957198-80-0
DICTIONARY FILE UPDATES: 9 DEC 2007 HIGHEST RN 957198-80-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10595691a.str



chain nodes :
7
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
5-7 7-8
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 12-14 13-16
14-15 15-16 15-17 16-20 17-18 17-21 18-19 18-23 19-20 21-22 22-23
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 7-8 12-14 13-16 14-15 15-16 15-17 16-20
17-18 17-21 18-19 18-23 19-20 21-22 22-23
normalized bonds :
8-9 8-13 9-10 10-11 11-12 12-13

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom

```
L1      STRUCTURE UPLOADED

=> s l1 sss ful
FULL SEARCH INITIATED 17:28:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -        1 TO ITERATE

100.0% PROCESSED        1 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

L2            0 SEA SSS FUL L1

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   172.10     172.31

STN INTERNATIONAL LOGOFF AT 17:28:56 ON 10 DEC 2007


Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 02   LMEDLINE coverage updated
 NEWS  3  JUL 02   SCISEARCH enhanced with complete author names
 NEWS  4  JUL 02   CHEMCATS accession numbers revised
 NEWS  5  JUL 02   CA/CAplus enhanced with utility model patents from China
 NEWS  6  JUL 16   CAplus enhanced with French and German abstracts
 NEWS  7  JUL 18   CA/CAplus patent coverage enhanced
 NEWS  8  JUL 26   USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS  9  JUL 30   USGENE now available on STN
 NEWS 10  AUG 06   CAS REGISTRY enhanced with new experimental property tags
 NEWS 11  AUG 06   FSTA enhanced with new thesaurus edition
 NEWS 12  AUG 13   CA/CAplus enhanced with additional kind codes for granted
                   patents
 NEWS 13  AUG 20   CA/CAplus enhanced with CAS indexing in pre-1907 records
 NEWS 14  AUG 27   Full-text patent databases enhanced with predefined
                   patent family display formats from INPADOCDB
 NEWS 15  AUG 27   USPATOLD now available on STN
 NEWS 16  AUG 28   CAS REGISTRY enhanced with additional experimental
                   spectral property data
 NEWS 17  SEP 07   STN AnaVist, Version 2.0, now available with Derwent
                   World Patents Index
 NEWS 18  SEP 13   FORIS renamed to SOFIS
 NEWS 19  SEP 13   INPADOCDB enhanced with monthly SDI frequency
```

```
NEWS 20  SEP 17  CA/CAplus enhanced with printed CA page images from
                 1967-1998
NEWS 21  SEP 17  CAplus coverage extended to include traditional medicine
                 patents
NEWS 22  SEP 24  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23  OCT 02  CA/CAplus enhanced with pre-1907 records from Chemisches
                 Zentralblatt
NEWS 24  OCT 19  BEILSTEIN updated with new compounds
NEWS 25  NOV 15  Derwent Indian patent publication number format enhanced
NEWS 26  NOV 19  WPIX enhanced with XML display format
NEWS 27  NOV 30  ICSD reloaded with enhancements
NEWS 28  DEC 04  LINPADOCDB now available on STN

NEWS EXPRESS   19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS     STN Operating Hours Plus Help Desk Availability
NEWS LOGIN     Welcome Banner and News Items
NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:53:08 ON 10 DEC 2007

=> file registry
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.21       0.21

FILE 'REGISTRY' ENTERED AT 17:53:15 ON 10 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    9 DEC 2007  HIGHEST RN 957198-80-0
DICTIONARY FILE UPDATES:   9 DEC 2007  HIGHEST RN 957198-80-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:
```

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10595691b.str



chain nodes :
7
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
5-7 7-8
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 12-14 13-16
14-15 15-16 15-17 16-20 17-18 17-21 18-19 18-23 19-20 21-22 22-23
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 7-8 12-14 13-16 14-15 15-16 15-17 16-20
17-18 17-21 18-19 18-23 19-20 21-22 22-23
normalized bonds :
8-9 8-13 9-10 10-11 11-12 12-13

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom

L1 STRUCTURE UPLOADED

=> s l1 sss ful
FULL SEARCH INITIATED 17:53:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 177.05 177.26

STN INTERNATIONAL LOGOFF AT 18:00:33 ON 10 DEC 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS	27	NOV 30	ICSD reloaded with enhancements
NEWS	28	DEC 04	LINPADOCDB now available on STN

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

```
Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:05:11 ON 10 DEC 2007

=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 18:05:40 ON 10 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    9 DEC 2007  HIGHEST RN 957198-80-0
DICTIONARY FILE UPDATES:   9 DEC 2007  HIGHEST RN 957198-80-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> e gw572016
E1            1     GW50/BI
E2            1     GW520/BI
E3            0 --> GW572016/BI
E4            1     GW63K/BI
E5            4     GW68/BI
E6            2     GW7/BI
E7            1     GW75/BI
E8            3     GWA/BI
E9            1     GWA11/BI
E10           2     GWAL/BI
E11           2     GWALIAR/BI
E12           1     GWANGYANGENSIS/BI

=>
Connecting via Winsock to STN
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS	27	NOV 30	ICSD reloaded with enhancements
NEWS	28	DEC 04	LINPADOCDB now available on STN

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:52:27 ON 11 DEC 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 06:52:37 ON 11 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 DEC 2007 HIGHEST RN 957336-90-2
DICTIONARY FILE UPDATES: 10 DEC 2007 HIGHEST RN 957336-90-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10595691c.str



chain nodes :
10 17 18 24
ring nodes :

```
1  2  3  4  5  6  7  8  9  11  12  13  14  15  16  19  20  21  22  23
chain bonds :
1-10  8-22  9-17  10-15  17-18  21-24
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9  11-12  11-16  12-13  13-14  14-15
 15-16  19-20  19-23  20-21  21-22  22-23
exact/norm bonds :
1-10  5-7  6-9  7-8  8-9  9-17  10-15  11-12  11-16  12-13  13-14  14-15  15-16
19-20  19-23  20-21  21-22  21-24  22-23
exact bonds :
8-22  17-18
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:CLASS  18:CLASS  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:CLASS



L1      STRUCTURE UPLOADED

=> s l1 sss ful
FULL SEARCH INITIATED 06:52:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     3405 TO ITERATE

100.0% PROCESSED     3405 ITERATIONS                                 5 ANSWERS
SEARCH TIME: 00.00.01

L2            5 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   172.10     172.31

FILE 'CAPLUS' ENTERED AT 06:53:06 ON 11 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 11 Dec 2007  VOL 147 ISS 25
FILE LAST UPDATED: 10 Dec 2007  (20071210/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
```

```
=> s l2
L3            3 L2

=> d l3

L3   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2005:451189  CAPLUS
DN   142:476214
TI   Erb family inhibitor and PI3K and/or Akt inhibitor for cancer treatment
IN   Dev, Inderjit Jumar; Gilmer, Tana Morgan; Rhodes, Cliford Nelson, III;
     Tansik, Robert L.
PA   Smithkline Beecham Corporation, USA
SO   PCT Int. Appl., 111 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2005046678        A1    20050526    WO 2004-US37027        20041105
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
             SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     EP 1682123          A1    20060726    EP 2004-810446         20041105
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS
     JP 2007510667       T     20070426    JP 2006-538522         20041105
     US 2007161665       A1    20070712    US 2006-595691         20060505
PRAI US 2003-518212P     P     20031107
     WO 2004-US37027     W     20041105
OS   MARPAT 142:476214
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d l3 ibib abs1-3
'ABS1-3' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
```

```
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d l3 ibib abs 1-3

L3   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:451189  CAPLUS
DOCUMENT NUMBER:          142:476214
TITLE:                    Erb family inhibitor and PI3K and/or Akt inhibitor for
                          cancer treatment
INVENTOR(S):              Dev, Inderjit Jumar; Gilmer, Tana Morgan; Rhodes,
                          Clifford Nelson, III; Tansik, Robert L.
PATENT ASSIGNEE(S):       Smithkline Beecham Corporation, USA
SOURCE:                   PCT Int. Appl., 111 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046678	A1	20050526	WO 2004-US37027	20041105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1682123	A1	20060726	EP 2004-810446	20041105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007510667	T	20070426	JP 2006-538522	20041105
US 2007161665	A1	20070712	US 2006-595691	20060505
PRIORITY APPLN. INFO.:			US 2003-518212P	P 20031107
			WO 2004-US37027	W 20041105

OTHER SOURCE(S): MARPAT 142:476214

AB The invention discloses a method for treating cancer in a mammal, as well as pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer. Preparation of inhibitors is described.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:120747 CAPLUS
DOCUMENT NUMBER: 142:219283
TITLE: Preparation of 1H-imidazo[4,5-c]pyridin-2-yl derivatives as inhibitors of Akt activity
INVENTOR(S): Heerding, Dirk A.; Clark, Tammy J.; Drewry, David H.; Leber, Jack Dale; Safonov, Igor; Yamashita, Dennis S.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 212 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011700	A1	20050210	WO 2004-US24340	20040728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004261214	A1	20050210	AU 2004-261214	20040728

CA 2534038	A1	20050210	CA 2004-2534038		20040728
EP 1653961	A1	20060510	EP 2004-779406		20040728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004012993	A	20061003	BR 2004-12993		20040728
CN 1859912	A	20061108	CN 2004-80028355		20040728
JP 2007500709	T	20070118	JP 2006-522030		20040728
IN 2006DN00264	A	20070810	IN 2006-DN264		20060116
MX 2006PA01134	A	20060411	MX 2006-PA1134		20060127
NO 2006000985	A	20060419	NO 2006-985		20060228
PRIORITY APPLN. INFO.:			US 2003-490851P	P	20030729
			US 2003-491055P	P	20030730
			US 2003-493101P	P	20030806
			US 2003-494752P	P	20030813
			US 2003-507014P	P	20030929
			US 2003-530847P	P	20031218
			WO 2004-US24340	W	20040728

OTHER SOURCE(S): MARPAT 142:219283
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein Het = 4-furazan-3-yl, 4-pyridinyl, 2-aminopyridin-4-yl, 2-amino-pyrimidin-5-yl, etc.; R1 = H, (un)substituted alkyl, cycloalkyl containing 1-4 heteroatoms; R4 = H, halo, (un)substituted alkyl, cycloalkyl, poly/cyclic aromatic ring; R7 = H, CONR9R10 and derivs., SO2NR9R10 and derivs., N(CH2)mNR9R10etc.; m = 6, where the carbon chain formed by m is optionally substituted; R9, R10 = independently H, (un)substituted alkyl, cycloalkyl etc.; with the exception of one compound; and their pharmaceutically acceptable salts, hydrates, solvates, and prodrugs] were prepared as inhibitors of protein kinase B activity. For example, II•xTFA was prepared via cyclocondensation of N-(1-Benzylpiperidin-4-yl)-2-chloropyridin-3,4-diamine (preparation given) with Et cyanoacetate, followed by Pd-coupling with Ph boronic acid, reaction with NaNO2 and NH2OH of acetonitrile intermediate, and Bn-deprotection. In an Akt inhibitory activity assay, III displayed IC50 values of 0.069, 0.038, and 0.032, against delta-PH domain of Akt1, Akt2, and Akt3, resp. Thus, I are useful in the treatment of cancer and arthritis (no data).
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:777793 CAPLUS
DOCUMENT NUMBER: 139:292251
TITLE: Preparation of imidazopyridines as kinase inhibitors
INVENTOR(S): Bailey, Nicholas; Bamford, Mark James; Garland, Stephen; Goodman, Krista B.; Haifeng, Cui; Hilfiker, Mark A.; Lee, Dennis; Panchal, Terence Aaron; Stavenger, Robert A.; Wilson, David Matthew; Witherington, Jason
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003080610		A1	20031002	WO 2003-GB1205	20030321
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003215753		A1	20031008	AU 2003-215753	20030321
EP 1490367		A1	20041229	EP 2003-744904	20030321
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005526802		T	20050908	JP 2003-578364	20030321
US 2005197328		A1	20050908	US 2004-508760	20040922
PRIORITY APPLN. INFO.:				GB 2002-6860	A 20020322
				WO 2003-GB1205	W 20030321

OTHER SOURCE(S): MARPAT 139:292251

GI



I



II III IV V

AB This patent concerns imidazopyridines (shown as I; variables defined below; e.g. 4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-ylamine) and physiol. acceptable salts and or N-oxides thereof, processes for their preparation, pharmaceutical compns. containing them and their use in medicine. For I, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6 with the proviso that at least one but not more than two of X1, X2, X3 and X4 = N; R1 is a 5-, or 6-membered heterocyclic group II, III, IV or V wherein X5 is a N or CR7: and X6 is a O, S or NR8; X7 and X8, which may be the same or different is a N or CR9; X9 is a O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and = N or R11; addnl. details are given in the claims. For Rho-kinase (ROCK) activity the compds. I of the examples have a pIC50 of 9 to 5.2; for mitogen and stress activated protein kinase-1 (Msk-1) activity the compds. I of the examples have a pIC50 value of 9.28-5.15. The compds. I are essentially non-toxic at therapeutically useful doses; thus no adverse effects were observed when compds. of the invention were administered to rats at a dose of 100 mg/kg.

Although no specific therapeutic applications are claimed, because of the inhibition by I of Msk-1, I should be useful for the treatment or prophylaxis of disorders associated with neuronal degeneration resulting from ischemic events or inflammatory conditions, e.g. cerebral stroke; also, because of the inhibition by I of Rho kinases, I should be useful for the treatment or prophylaxis of cardiovascular and neuroinflammatory diseases. More than 300 example prepns. and/or characterization data for I are included. For example, [4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine was prepared in 4 steps (88, 94, 37 and 43 % yields, resp.) starting from 4-methoxy-3-nitropyridine hydrochloride and ethylamine and involving intermediates ethyl(3-nitropyridin-4-yl)amine, N'-ethylpyridine-3,4-diamine and (1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 06:52:27 ON 11 DEC 2007)

FILE 'REGISTRY' ENTERED AT 06:52:37 ON 11 DEC 2007
L1 STRUCTURE UPLOADED
L2 5 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 06:53:06 ON 11 DEC 2007
L3 3 S L2

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.49	184.80
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:56:26 ON 11 DEC 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/CAplus enhanced with utility model patents from China

```
 NEWS  6  JUL 16  CAplus enhanced with French and German abstracts
 NEWS  7  JUL 18  CA/CAplus patent coverage enhanced
 NEWS  8  JUL 26  USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS  9  JUL 30  USGENE now available on STN
 NEWS 10  AUG 06  CAS REGISTRY enhanced with new experimental property tags
 NEWS 11  AUG 06  FSTA enhanced with new thesaurus edition
 NEWS 12  AUG 13  CA/CAplus enhanced with additional kind codes for granted
                  patents
 NEWS 13  AUG 20  CA/CAplus enhanced with CAS indexing in pre-1907 records
 NEWS 14  AUG 27  Full-text patent databases enhanced with predefined
                  patent family display formats from INPADOCDB
 NEWS 15  AUG 27  USPATOLD now available on STN
 NEWS 16  AUG 28  CAS REGISTRY enhanced with additional experimental
                  spectral property data
 NEWS 17  SEP 07  STN AnaVist, Version 2.0, now available with Derwent
                  World Patents Index
 NEWS 18  SEP 13  FORIS renamed to SOFIS
 NEWS 19  SEP 13  INPADOCDB enhanced with monthly SDI frequency
 NEWS 20  SEP 17  CA/CAplus enhanced with printed CA page images from
                  1967-1998
 NEWS 21  SEP 17  CAplus coverage extended to include traditional medicine
                  patents
 NEWS 22  SEP 24  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 23  OCT 02  CA/CAplus enhanced with pre-1907 records from Chemisches
                  Zentralblatt
 NEWS 24  OCT 19  BEILSTEIN updated with new compounds
 NEWS 25  NOV 15  Derwent Indian patent publication number format enhanced
 NEWS 26  NOV 19  WPIX enhanced with XML display format
 NEWS 27  NOV 30  ICSD reloaded with enhancements
 NEWS 28  DEC 04  LINPADOCDB now available on STN

 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:59:21 ON 11 DEC 2007

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:59:37 ON 11 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 DEC 2007 HIGHEST RN 957336-90-2
DICTIONARY FILE UPDATES: 10 DEC 2007 HIGHEST RN 957336-90-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10595691c.str



chain nodes :
10 17 18 24
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 19 20 21 22 23
chain bonds :
1-10 8-22 9-17 10-15 17-18 21-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15
 15-16 19-20 19-23 20-21 21-22 22-23
exact/norm bonds :
1-10 5-7 6-9 7-8 8-9 9-17 10-15 11-12 11-16 12-13 13-14 14-15 15-16
19-20 19-23 20-21 21-22 21-24 22-23
exact bonds :
8-22 17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS

```
L1      STRUCTURE UPLOADED

=>  s l1 fam ful
FULL SEARCH INITIATED 09:59:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      816 TO ITERATE

100.0% PROCESSED      816 ITERATIONS                                  2 ANSWERS
SEARCH TIME: 00.00.01

L2            2 SEA FAM FUL L1

=> d l2 1-2

L2   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   852023-81-5  REGISTRY
ED   Entered STN:  10 Jun 2005
CN   1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-
     c]pyridin-2-yl]-, trihydrochloride (9CI)  (CA INDEX NAME)
MF   C15 H19 N7 O2 . 3 Cl H
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
CRN  (607373-68-2)
```



```
     ●3  HCl

               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2   ANSWER 2 OF 2  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   607373-68-2  REGISTRY
ED   Entered STN:  21 Oct 2003
CN   1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-
     c]pyridin-2-yl]-  (CA INDEX NAME)
OTHER NAMES:
CN   4-[1-Ethyl-7-[(piperidin-4-yl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-
     ylamine
MF   C15 H19 N7 O2
CI   COM
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	72.05	72.26

FILE 'CAPLUS' ENTERED AT 10:00:36 ON 11 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Dec 2007 VOL 147 ISS 25
FILE LAST UPDATED: 10 Dec 2007 (20071210/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3 3 L2

=> d l3 ibib abs 1-3

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:451189 CAPLUS
DOCUMENT NUMBER: 142:476214
TITLE: Erb family inhibitor and PI3K and/or Akt inhibitor for

cancer treatment
INVENTOR(S): Dev, Inderjit Jumar; Gilmer, Tana Morgan; Rhodes, Cliford Nelson, III; Tansik, Robert L.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046678	A1	20050526	WO 2004-US37027	20041105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1682123	A1	20060726	EP 2004-810446	20041105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007510667	T	20070426	JP 2006-538522	20041105
US 2007161665	A1	20070712	US 2006-595691	20060505

PRIORITY APPLN. INFO.: US 2003-518212P P 20031107
WO 2004-US37027 W 20041105
OTHER SOURCE(S): MARPAT 142:476214
AB The invention discloses a method for treating cancer in a mammal, as well as pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer. Preparation of inhibitors is described.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:120747 CAPLUS
DOCUMENT NUMBER: 142:219283
TITLE: Preparation of 1H-imidazo[4,5-c]pyridin-2-yl derivatives as inhibitors of Akt activity
INVENTOR(S): Heerding, Dirk A.; Clark, Tammy J.; Drewry, David H.; Leber, Jack Dale; Safonov, Igor; Yamashita, Dennis S.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 212 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011700	A1	20050210	WO 2004-US24340	20040728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

AU	2004261214	A1	20050210	AU 2004-261214	20040728
CA	2534038	A1	20050210	CA 2004-2534038	20040728
EP	1653961	A1	20060510	EP 2004-779406	20040728
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR	2004012993	A	20061003	BR 2004-12993	20040728
CN	1859912	A	20061108	CN 2004-80028355	20040728
JP	2007500709	T	20070118	JP 2006-522030	20040728
IN	2006DN00264	A	20070810	IN 2006-DN264	20060116
MX	2006PA01134	A	20060411	MX 2006-PA1134	20060127
NO	2006000985	A	20060419	NO 2006-985	20060228

PRIORITY APPLN. INFO.:	US 2003-490851P	P	20030729
	US 2003-491055P	P	20030730
	US 2003-493101P	P	20030806
	US 2003-494752P	P	20030813
	US 2003-507014P	P	20030929
	US 2003-530847P	P	20031218
	WO 2004-US24340	W	20040728

OTHER SOURCE(S): MARPAT 142:219283
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein Het = 4-furazan-3-yl, 4-pyridinyl, 2-aminopyridin-4-yl, 2-amino-pyrimidin-5-yl, etc.; R1 = H, (un)substituted alkyl, cycloalkyl containing 1-4 heteroatoms; R4 = H, halo, (un)substituted alkyl, cycloalkyl, poly/cyclic aromatic ring; R7 = H, CONR9R10 and derivs., SO2NR9R10 and derivs., N(CH2)mNR9R10etc.; m = 6, where the carbon chain formed by m is optionally substituted; R9, R10 = independently H, (un)substituted alkyl, cycloalkyl etc.; with the exception of one compound; and their pharmaceutically acceptable salts, hydrates, solvates, and prodrugs] were prepared as inhibitors of protein kinase B activity. For example, II•xTFA was prepared via cyclocondensation of N-(1-Benzylpiperidin-4-yl)-2-chloropyridin-3,4-diamine (preparation given) with Et cyanoacetate, followed by Pd-coupling with Ph boronic acid, reaction with NaNO2 and NH2OH of acetonitrile intermediate, and Bn-deprotection. In an Akt inhibitory activity assay, III displayed IC50 values of 0.069, 0.038, and 0.032, against delta-PH domain of Akt1, Akt2, and Akt3, resp. Thus, I are useful in the treatment of cancer and arthritis (no data).
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:777793 CAPLUS
DOCUMENT NUMBER: 139:292251
TITLE: Preparation of imidazopyridines as kinase inhibitors
INVENTOR(S): Bailey, Nicholas; Bamford, Mark James; Garland, Stephen; Goodman, Krista B.; Haifeng, Cui; Hilfiker, Mark A.; Lee, Dennis; Panchal, Terence Aaron; Stavenger, Robert A.; Wilson, David Matthew; Witherington, Jason

PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080610	A1	20031002	WO 2003-GB1205	20030321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003215753	A1	20031008	AU 2003-215753	20030321
EP 1490367	A1	20041229	EP 2003-744904	20030321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005526802	T	20050908	JP 2003-578364	20030321
US 2005197328	A1	20050908	US 2004-508760	20040922
PRIORITY APPLN. INFO.:			GB 2002-6860 A	20020322
			WO 2003-GB1205 W	20030321

OTHER SOURCE(S): MARPAT 139:292251
GI





AB This patent concerns imidazopyridines (shown as I; variables defined below; e.g. 4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-ylamine) and physiol. acceptable salts and or N-oxides thereof, processes for their preparation, pharmaceutical compns. containing them and their use in medicine. For

I, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6 with the proviso that at least one but not more than two of X1, X2, X3 and X4 = N; R1 is a 5-, or 6-membered heterocyclic group II, III, IV or V wherein X5

is a N or CR7; and X6 is a O, S or NR8; X7 and X8, which may be the same or different is a N or CR9; X9 is a O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and = N or R11; addnl. details are given in the claims. For Rho-kinase (ROCK) activity the compds. I of the examples have a pIC50 of 9 to 5.2; for mitogen and stress activated protein kinase-1 (Msk-1) activity the compds. I of the examples have a pIC50 value of 9.28-5.15. The compds. I are essentially non-toxic at therapeutically useful doses; thus no adverse effects were observed when compds. of the invention were administered to rats at a dose of 100 mg/kg. Although no specific therapeutic applications are claimed, because of the inhibition by I of Msk-1, I should be useful for the treatment or prophylaxis of disorders associated with neuronal degeneration resulting from ischemic events or inflammatory conditions, e.g. cerebral stroke; also, because of the inhibition by I of Rho kinases, I should be useful for the treatment or prophylaxis of cardiovascular and neuroinflammatory diseases. More than 300 example prepns. and/or characterization data for I are included. For example, [4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine was prepared in 4 steps (88, 94, 37 and 43 % yields, resp.) starting from 4-methoxy-3-nitropyridine hydrochloride and ethylamine and involving intermediates ethyl(3-nitropyridin-4-yl)amine, N'-ethylpyridine-3,4-diamine and (1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.60	86.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

STN INTERNATIONAL LOGOFF AT 10:08:10 ON 11 DEC 2007